Oct. 21, 2013
The €400 million deal between the Swiss Σellas Life Sciences Group and Chinese Fochon Pharma, (a member of the the Fosun Pharma Group), signed on October 21, 2013 is another milestone in the evolution of the Chinese life sciences industry. The cooperation of Σellas with Fochon Pharma concerns the development of two innovative therapies for Type II diabetes and lung cancer which were discovered by Fochon Pharma and whose worldwide rights have been secured by Σellas in order to develop them internationally. This transaction highlights the reversing trend, whereby China’s improving R&D capabilities allow it to export innovative technologies, rather than only to import them. As the Chinese capabilities continue to mature, we can expect additional transactions of this sort in years to come.